Receiving a cancer diagnosis at any age is a life-altering experience, but for adolescents and young adults (AYAs) already navigating a potentially tumultuous time of life, the challenges can be amplified.

 such as Stacy Leung who, at just 23 years old, received a diagnosis of stage 2 triple-negative breast cancer. She received a second diagnosis of breast cancer 12 years later, as she was preparing for her wedding. Leung said she found empowerment in planning.

“I was at a point where I was working with a wedding event planner, I [already] got my dress and I’m like, ‘OK, this is what’s happening,’” Leung explained. “Having the unknown was the hardest part. Once I had a game plan, it was fine because I knew exactly what the moves were and what was going to happen.”

Leung’s is the latest among countless stories we have had the privilege to report on during the first 25 years of MJH Life Sciences®.

Since we started quarter century ago with a single brand, we have launched thousands of video programs, developed cutting-edge conferences and held thousands of virtual and live events, all while tirelessly covering health care news in print and online.

The driving force behind our evolution remains our passion for improving health care. We are grateful to you, our readers, for joining us on this journey.

Elsewhere in this issue, we take a deep dive into some of the 

latest treatment advancements for small cell lung cancer

, offer insights into how best to prepare for a virtual visit with your physician and feature 

answers to patients’ questions on breast cancer

Throughout these pages, you’ll find personal stories and expert insights. As always, we hope you find them inspirational and informative. Thank you for reading.

Mike Hennessy Jr.
President and CEO
MJH Life Sciences

Articles

In this Fall issue of CURE, we focus on AYAs with cancer, latest treatments in small cell lung cancer, preparing for a virtual visit and answering common questions about breast cancer.

Choices About Cancer Treatment During a Tumultuous Time

Although advancements in treatments for small cell lung cancer (SCLC) are scarce for this aggressive cancer type, recent regulatory developments and trial results indicate that we are on the precipice of a new era for patients and providers alike.

We put a spotlight on these big steps forward and discuss what they mean for the future of SCLC treatment in this seasonal issue of CURE.

“The limited options of treatment for patients with small cell lung cancer is the reality that we all confront — but that is not for lack of trying,” said Dr. Taofeek K. Owonikoko, executive director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center in Baltimore.

However, a glimmer of hope emerged with the approval of Imdelltra (tarlatamab-dlle) by the Food and Drug Administration (FDA) in May 2024 to treat patients with extensive-stage (ES) SCLC.

This groundbreaking immunotherapy, known as a bispecific T-cell engager therapy, offers an innovative approach to treating SCLC. Imdelltra works by binding to both cancer cells and immune cells, bringing them close together, which activates the immune system to attack and destroy the tumor.

Elsewhere this year, results of the landmark phase 3 ADRIATIC trial of Imfinzi (durvalumab), an immunotherapeutic antibody known as a checkpoint inhibitor, attracted plenty of attention in discussions at the American Society of Clinical Oncology Annual Meeting. The findings have also been published in the 

Imfinzi, which was initially approved by the FDA in 2020 in combination with etoposide and either carboplatin or cisplatin as first-line treatment of ES-SCLC, was tested in ADRIATIC in patients with limited-stage (cancer on one side of the chest only) SCLC and whose disease had not progressed after chemoradiotherapy.

“This is perhaps the only breakthrough advancement in the past 30 years, because we have been using chemotherapy and radiation to treat [patients with] limited-stage small cell lung cancer since more than 30 years ago. However, this is the first time a new treatment has been shown to be able to prolong life for almost two years,” said Dr. Yuanbin Chen of the Cancer and Hematology Centers in Grand Rapids and Norton Shores, Michigan.

Imfinzi blocks the immune-dampening protein PD-L1, thereby helping the immune system detect and attack cancer. Based on the results of the ADRIATIC trial, the FDA has accepted a supplemental biologics license application for Imfinzi and granted priority review, with a regulatory decision expected later this year.

In discussing these developments, we also delve into the side effects associated with these treatments and acknowledge the continued need for a cure for SCLC — one of the more virulent cancers.

“We’re still far, far away from where we need to be, which is, how do we transform cancer from being a very mortal diagnosis to something that people can survive?” said Owonikoko.

For more news on cancer updates, research and education, don’t forget to 

subscribe to CURE®’s newsletters here.

Editor's Page

Dr. Debu Tripathy, editor-in-chief of CURE magazine, discusses the advancements made in small cell lung cancer.

A New Era in Small Cell Lung Cancer Treatment

For Sabrina Potts, the approval by the Food and Drug Administration (FDA) of Imdelltra (tarlatamab-dlle) in May 2024 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) was an answer to her prayers.

Potts, now 58, received her diagnosis of SCLC in mid-2023. Amid a tumultuous treatment journey, she says the prospect of Imdelltra’s approval “gave me a reason to keep on going.”

“For a while, things were looking a little grim,” says Potts, who lives in Plumville, Pennsylvania. “And then, this really uplifted me.

“You know, I had been praying for something, a miracle, anything. I’m a true believer in God. And I do believe that he has a hand in all this.”

Before her diagnosis, Potts says, she was energetic, and had worked as a nurse for 25 years before retiring 15 years prior. ”I got the lung cancer diagnosis, and I started going downhill from there,” she says.

“After having severe upper respiratory infections and visiting my primary care provider multiple times, the physician’s assistant, Megan Shugarts, ordered chest X-rays and found a large tumor in my right lung,” Potts says. “Later I began treatment with Dr. Daniel Petro, and his outstanding team. After being seen by them everything went into fast speed, or seemed like it.”

Potts, who is being treated at UPMC Hillman Cancer Center in Pittsburgh, learned that her cancer had spread to her liver and her lymph nodes, and was treated with chemotherapy and radiation. By early 2024, it had further metastasized to areas including her bones and her stomach. She was hospitalized for pneumonia, and then for pain from a rib that had been fractured by persistent coughing.

She began treatment with Imdelltra in June, and says by late August, she felt better than she had prior to her diagnosis. Regarding side effects, in addition to a headache after her first treatment, she has experienced nausea, fever, extreme lethargy, increased pain and an unsteady gait, she says.

Imdelltra is a type of immunotherapy known as a bispecific T-cell engager, or BiTE therapy, which binds to both cancer cells and immune cells, bringing them into close proximity and allowing the patient’s own T cells to attack tumor cells.

“It essentially forces an interaction between the tumor and the T cells that are otherwise repelling or ignoring one another,” says Dr. Carl Gay of the Department of Thoracic/Head and Neck Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. “In doing so, the T cells finally gain access to the tumor, and seemingly recognize they’ve been sleeping on the job, and go about their expected role of attacking the tumor and eliminating at least a portion, if not, in some cases, nearly all of the tumor in some of the patients that have received this therapy.”

FDA approval of Imdelltra for patients with ES-SCLC

 (cancer that has spread throughout the lung to the other lung, or to other parts of the body, according to the American Cancer Society) with disease progression on or after platinum-based chemotherapy was based on phase 2 results from the 

 presented at the 2023 European Society for Medical Oncology Congress and published in 

Among patients with relapsed/refractory ES-SCLC whose disease progressed after treatment with platinum-based chemotherapy, the objective response rate (patients who responded partially or completely to treatment) was 40%, with a median duration of response of 9.7 months, the FDA reported.

According to the FDA, the prescribing information for Imdelltra includes a boxed warning for serious or life-threatening cytokine release syndrome (CRS) and neurologic toxicity including immune effector cell-associated neurotoxicity syndrome (ICANS), both consequences of exuberant activation of the immune system and injury to normal cells.

CRS involves symptoms such as fever, nausea, rash, headache, low blood pressure, rapid heartbeat and difficulty breathing after the rapid release of proteins known as cytokines into the blood. ICANS may have symptoms including delirium, confusion, seizures and language difficulties.

“You’re awakening the immune system, and that can be good, bad or even both at the same time,” says Gay.

The most common side effects experienced by more than 20% of patients included CRS, fatigue, pyrexia (fever), dysgeusia (altered taste), decreased appetite, musculoskeletal pain, constipation, anemia and nausea, the agency reported, noting that the most common grade 3 (severe) or 4 (life-threatening) laboratory abnormalities among more than 5% of patients were decreased lymphocytes (a type of white blood cell), decreased sodium, increased uric acid, decreased total neutrophils (a type of white blood cell), decreased hemoglobin (a protein in red blood cells), increased activated partial thromboplastin time (slow blood clotting) and decreased potassium.

“Fortunately, these side effects with [Imdelltra] have proved to be mild and manageable, at least in the trials that led to its approval,” Gay says. “I think we’re all now getting our first experience with treating patients like this in the standard of-care setting.”

Treatment advancements for SCLC are few and far between, experts note. It has been traditionally considered one of the most aggressive and treatment-refractory cancers. Physicians who spoke with 

cite obstacles to treatment such as a tendency for SCLC to be diagnosed at late stages and the frequency with which patients relapse after initially responding to treatment.

“We’ve suffered through decades of disappointment in small cell lung cancer, or maybe modest advances at best,” Gay says.

“The limited options of treatment for patients with small cell lung cancer is the reality that we all confront — but that is not for lack of trying,” says Dr. Taofeek K. Owonikoko, executive director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center in Baltimore. 

Owonikoko is also the senior associate dean of cancer programs at University of Maryland School of Medicine and the associate vice president of cancer programs at University of Maryland, Baltimore.

“Unlike other forms of lung cancer, where we now have more than 30 approved drugs for, comparatively speaking, a cancer type that starts in the same organ system as small cell lung cancer, one key difference between small cell and non-small cell types of lung cancer is the fact that the past 20 years brought a lot of revolution and innovation in carving out discrete populations of non-small lung cancer patients that we used to lump together as a single cancer type and recognizing them as different from one another, and potentially also responding to different treatment approaches,” Owonikoko says. “So we’ve gone from looking at non-small cell lung cancer as just … two or three different types of cancer … to where we now define them by a mutation that is present within the tumor cells, along with certain expression of biomarkers like PD-L1, HER2, and c-MET present on the surface of the tumors. And combining that approach with efforts to develop new drugs resulted in a plethora of therapeutic options for patients with non-small cell lung cancer. Small cell lung cancer, on the other hand, continues to be viewed as just one disease entity. And we treat all those patients as the same. I think that approach has contributed in no small way to the limited success that we’ve witnessed in the small cell space.”

'Nothing Has Recurred, Nothing Has Advanced'

It was late 2018 when Jennifer Sanborn began experiencing a dry cough, something a physician’s assistant attributed to bronchitis and treated with antibiotics. After the cough persisted for a month, Sanborn’s physician ordered a chest X-ray, which revealed a mass in her right lung.

Within two weeks Sanborn had connected with Dr. Yuanbin Chen of the Cancer and Hematology Centers in Grand Rapids and Norton Shores, Michigan, and had begun a course of chemotherapy and radiation. Chen then approached her about potentially participating in a clinical trial.

“I instantly said, ‘Yes, of course,’” recalls Sanborn, now 65, who lives in Michigan.

Chen was among the researchers on the landmark phase 3 ADRIATIC trial of Imfinzi (durvalumab). The drug, an immunotherapy that the FDA had approved in 2020 in combination with etoposide and either carboplatin or cisplatin as 

 following results of the CASPIAN trial, was tested in ADRIATIC among patients such as Sanborn who had limited-stage (cancer that is only on one side of the chest, according to the American Cancer Society) SCLC and whose disease had not progressed after chemoradiotherapy. 

Results of the trial, which made waves earlier this year at the American Society of Clinical Oncology Annual Meeting and were published in the 

, showed that at a median follow-up of 37.2 months, the median overall survival (the time a patient lives following treatment, regardless of disease status) was 55.9 months among patients treated with Imfinzi versus 33.4 months among patients treated with placebo. Median progression-free survival (how long a patient lives without their disease spreading or worsening) was 16.6 months and 9.2 months, respectively.

“This is perhaps the only breakthrough advancement in the past 30 years, because we have been using chemotherapy and radiation to treat [patients with] limited-stage small cell lung cancer since more than 30 years ago. However, this is the first time a new treatment has been shown to be able to prolong life for almost two years,” Chen says.

An immunotherapy known as a monoclonal antibody, Imfinzi “works by helping a patient’s immune system, to allow a patient’s own immune system to go attack the cancer and shrink the cancer and kill the cancer cell,” Chen says. Imfinzi specifically blocks the protein PD-L1, which helps the immune system detect and attack cancer.

Researchers reported that 24.3% of patients treated with Imfinzi experienced grade 3 or 4 side effects, with side effects leading to treatment discontinuation in 16.3% of patients and death in 2.7% of patients. Any-grade pneumonitis/radiation pneumonitis (inflammation of the lung tissue) was reported in 38% of patients treated with Imfinzi.

After her initial treatment, Sanborn says she felt like she came down with the flu, experiencing aches, chills and sickness to her stomach.

She initially received scans every three months and is now checked every six months, she says. “Nothing has recurred, nothing has advanced, nothing. I’ve never heard the word ‘remission’ because I don’t know if that exists in this cancer area,” she says.

Over time, her mindset toward scans has changed, she explains.

“[Initially] you’re … looking for days to get the results, and it’s like [you’re] on pins and needles,” she says. “And now I’m to the point where I get them, and I am not on pins and needles. I don’t live for that MRI and CT scan, whereas before, that’s what I was living for, just to be clear, you know? It’s like, ‘Am I going to be OK? Is this just going to come back? Am I going to have to go through the chemo again?’ And no. And I wondered that I’d ever get to this point where I was not dreading that and looking forward to it at the same time.”

Elsewhere, progress continues, with an announcement in August 2024 that the FDA had granted a breakthrough therapy designation to GSK5764227 (GSK’227), an antibody-drug conjugate being evaluated for the treatment of patients with ES-SCLC. Antibody-drug conjugates deliver chemotherapy directly to cancer cells with the intention of sparing healthy cells from harmful effects.

Although this year has seen great strides in treating patients with SCLC, Owonikoko says that unmet needs remain — namely, a cure.

“While the ADRIATIC trial, the CASPIAN trial [and] the [DeLLphi-301] trial [have] all shown good advances in what these treatment options bring for our patients, we’re still far, far away from where we need to be,” he says, “which is, how do we transform small cell lung cancer from being a very mortal diagnosis to something that people can survive? We are beginning to move ahead from wanting to just turn cancer into a chronic illness to trying to cure it.

“And all of these options, while they are really beneficial and with great promise for some patient subset, I don’t think we’re at a point where we can be confident that [the] majority of our patients will be cured because of these treatments that we do have now. Is it possible that as we gain more experience that cure could be the expected outcome for some patients? I will say possibly, but for [the] majority of our patients, the current progress is still not something that we can rely on as a cure. It’s benefiting patients, no doubt, and making patients live longer, but not being able to cure a lot of our patients remains an area of unmet need.”

Potts has advice for fellow patients with SCLC: “Never give up,” she says. “I do believe in these doctors. God has given them a gift. And let them use their gift to help you.”

Feature

With pivotal trial results and an approval from the FDA, the landscape is changing for patients with small cell lung cancer.

‘Never Give Up’: Treatment Breakthroughs Arrive for SCLC

At 23 years old in 2011, Stacy Leung achieved two major milestones: moving to Baltimore from Philadelphia and starting a career at Morgan Stanley. However, when she received a diagnosis of stage 2 triple-negative breast cancer, the momentum in her life temporarily came to a stop.

When deciding on treatment options, Leung’s mother told her to follow whatever the doctors said to do. Trusting her care team, she underwent a lumpectomy to remove the tumor and surrounding breast tissue, chemotherapy and radiation, but not a mastectomy (surgical removal of one or both breasts) or any breast reconstruction. Before the treatment began, Leung also met with a fertility doctor to discuss fertility preservation.

Receiving a diagnosis of cancer at a young age means Leung is in the adolescent and young adult (AYA) category. Patients with cancer in this age group typically experience unique challenges at this earlier stage in life. During this time of many unknowns, AYAs must navigate the treatment decision-making process, which may be an added stressor for patients and their families. Nevertheless, Leung faced this match of treatment decision-making a second time.

Twelve years later in 2023, as Leung prepared for her wedding, a routine MRI scan for imaging and surveillance showed that she had entirely new chapter of her life, her diagnosis came as a shock to her and her fiance.  

“I was at a point where I was working my dress [already] and I’m like, ‘OK, this is what’s happening,’” Leung explains. “Having the unknown was the hardest part. Once I had a game plan, it was fine because I knew exactly what the moves were and what was going to happen.”

Now working as a physician’s assistant in the surgery department of a Philadelphia hospital, Leung knew precisely what she planned to do surgery wise. She underwent a bilateral mastectomy to remove both of her breasts. However, choosing the type of cosmetic procedure to receive following the mastectomy was an unexpected challenge. A passionate boxer at her local Muay Thai gym,  Leung did not want to give up her chance of being able to spar again. She spoke extensively with her plastic and breast surgeons to advocate for her best quality of life and being able to do what she loves. 

“I wanted to be able to hit pads, be able to spar and have my peak mobility. I also wanted the quickest recovery," Leung says. "Initially, I was gonna go in with just flat surgery and not have any reconstruction done. But my cousin said, ‘You should probably consider having something done because you don’t know if it’s going to impact you later in life or your mental health [regarding your femininity].’”

After some consideration, Leung decided on bilateral implants, although her plastic surgeon disagreed and tried convincing her to pursue a flat or other cosmetic options. Nevertheless, she stood her ground after having done her research and ultimately made the decision that best suited her body and lifestyle.

The age range for AYAs with cancer is between 15 and 39 years old, according to the National Cancer Institute. Although the range is significant, AYAs account for approximately 4% of all cancer diagnoses. In 2024, the majority of cancer types within this patient population include breast, thyroid, testicular cancers and melanoma of the skin, statistics from the National Cancer Institute state. A growing number of cancer centers are establishing AYA programs to ensure that tailored services such as fertility planning, job counseling and psychological support are available.

For AYAs who have received diagnoses of cancer, it can be an overwhelming and challenging time. To start, having a close-knit support system is essential, says Dr. Michael Roth, co-director of the Adolescent and Young Adult Program at The University of Texas MD Anderson Cancer Center in Houston. Specifically, finding a provider and care team that feels comfortable and trustworthy is important because a lot of time, effort and knowledge is shared, Roth explains.

Before making treatment decisions, taking notes at appointments and writing down questions ahead of time can help AYAs and their families through an intimidating time, Roth says. Stages in AYAs’ lives should be considered, he emphasizes, especially when deciding on a treatment.

“Highest on the list is what type of treatment will be best for [AYAs] and their cancer, and how to maximize cure rates and make sure there aren’t too many side effects, both short term and long term,” Roth says. “It’s also important to think of other areas of life that are relevant, whether [the patients] are in school, working, [if they are] in a relationship and [have] plans of family building.”

Considerations of quality of life and prospects should also be addressed with care teams before choosing a treatment, Roth says. Thinking about goals for care and personal life is significant during this stage, he notes.

“For every individual, they have the right to determine what is most important in their treatment and their lives, during and after treatment,” Roth adds. “I want [AYAs] to be proud of themselves as they go through this process and this journey. This is equivalent to working five jobs, trying to be an AYA and just living life. Know that the team is here to support you, whether it’s your family, friends or medical team — lean on others for support.”

At 19 years old and right before her sophomore year at the University of Washington, Mia Sandino thought she sprained her knee — only to learn that she had a 2 1/2-inch benign tumor in her tibia, a bone in the shin. After meeting with an orthopedic surgeon, Sandino and her mom, Serena, were told there were two options: She could either miss school for an entire year and replace the tibia, knee and femur (thigh bone) with metal and a hinge joint or miss school for a few months and undergo a minimally invasive procedure to remove the tumor and fix her broken bone with bone cement.

Before making this tough decision, Sandino and her mom consulted the doctor, asking what option she would choose if her child were going through this process. Undergoing the minimally invasive procedure, Sandino’s doctor said, would be the option she would choose because of Sandino’s adamancy toward academics.

Sandino had her tumor removed five days after the meeting with her doctor. Yet, when the results returned, the pathology revealed that the back half of the tumor was stage 3 osteosarcoma, a type of bone cancer that occurs in children and AYAs. This led to only one choice: an 8 1/2-hour surgery to replace her tibia, knee and femur with 15 inches of metal.

Her treatment following the surgery included chemotherapy drugs — one of which caused her to lose 15% of her hearing in higher frequencies. The chemotherapy also caused intense heartburn that made her feel like she was having a heart attack, she says.

“I told my team, ‘I don’t want to be on this drug,’ and that was a way I could control my own treatment plan,” says Sandino, now 25, of Los Angeles. “They swapped it out for a less-toxic drug that still would work against the cancer.”

Advocating for herself when the side effects became intolerable was essential, but also advocating when she could no longer enjoy the food she loved. Receiving a cancer treatment, Piqray (alpelisib), that raised her blood sugar meant not being able to eat sushi because of the type of rice, she says. Sandino considered her quality of life and how she couldn’t go out to restaurants or bars with friends because of her sugar restrictions.

“Constantly having to watch myself and having gut inflammation just wasn’t it,” she says. “For me, it’s focusing on quality over quantity at the end of the day. And I realized I didn’t want to live that way, so I stopped the treatment and thankfully, I’m in a good spot.

“A lot of people will choose the quantity because they want to see how far they can get [survival-wise]. But at the same time, I’m in the position where I don’t want the people I love to have their last memories of me [to be of me] suffering extremely.”

Before making difficult decisions about treatments, it’s important for AYAs to have a support system to rely on, whether it’s to talk things through or just to be present in the moment. Having to experience this process on “an island” and making decisions alone is extremely overwhelming, says Roth, especially because doubt about those decisions enters the picture.

“We want our patients to make informed decisions with the individuals who they love most and those who love them most,” Roth says. “With the caveat that when they are diagnosed with cancer, often, everyone and their mother wants to help, so sometimes it gets frustrating because everyone is calling and reaching out saying, ‘Oh, you should do this or go to this provider.’ That often causes more anxiety as opposed to more help.”

Receiving support from other professionals can also be helpful, says Cynthia Gerhardt, chief clinical research officer at Nationwide Children’s Hospital in Columbus, Ohio. She notes that physicians and nurses may suggest meeting a psychosocial support provider, which is very important. Having a support system that allows AYAs to be open and ask questions about things they need is helpful, Gerhardt says, whether patients and their families want more information or a little bit at a time.

“Getting information about what the treatment options are and talking that through with the support team and health care providers is really key in that process,” Gerhardt explains. “There are some AYAs that will rely on their health care team to make those decisions and others want to have a bigger role. It’s important to share where they fall along that continuum.”

Because the age range of AYAs is broad and includes several life stages and milestones, the amount of support an AYA may want can vary. Younger teenagers may not have the perspective to think about how their lives may look five or 10 years in the future, Gerhardt says. AYAs in this age group may need more support from their families and health care teams to help guide their decisions or may also defer their decision to their parents.

For young adults, other aspects may “factor into the equation,” Gerhardt explains, such as their own children. Once these factors play a role in treatment decision-making, choices can become very individualized, she says. Regardless, having a health care team and supportive network that can help navigate difficult choices is important.

Finding a Voice in the Treatment Landscape

For Leung and Sandino, advocating for themselves and wisely considering how their treatment options would best suit their lifestyles were important. For many AYAs, each life stage “comes with its own challenges,” says Katie Darabos, professor at the Rutgers School of Public Health in New Brunswick, New Jersey. As AYAs approach their mid-20s, it can be a challenge recognizing that they can make decisions on their own, she notes. However, insight from parents, a significant other or a close friend may be helpful — it all depends on how involved AYAs would like to be in their treatment decision-making, Darabos says.

“We do have a lot of older AYAs showing up to medical appointments with their parents or significant others because it’s another voice in the room that really helps them take in all of that information from oncology providers,” Darabos adds. “It’s really hard to sit in an office by yourself and try to take in all of that information.”

Still, independence plays a key role in AYAs’ lives when they’re in their 20s, Roth says. During this time in their lives, they’ve likely gained independence and don’t want to give it up, he says.

“They want to continue to do what their peers and their friends are doing, become more independent, meet partners, grow families — it’s a critical time in their lives,” Roth adds. “Cancer, in some ways, takes patients away from what their peers are doing, and they see them progressing through life.

“Many AYAs’ lives could be put on hold … [and] it’s really hard to give up independence, it’s hard to potentially move back in with family and have others caring for you when you were used to doing everything for yourself,” he emphasizes. “With that said, we all need help and support at different times in our lives.

“This is one of those times where AYAs need to accept help. It’s just too challenging of a period to do it by yourself.”

During the cancer treatment process, it's important for adolescents and young adults to balance independence while seeking support from loved ones.

CURE Fall 2024

Choices About Cancer Treatment During a Tumultuous Time

A New Era in Small Cell Lung Cancer Treatment

‘Never Give Up’: Treatment Breakthroughs Arrive for SCLC

Making Dynamic Decisions as AYAs During the Cancer Treatment Process

Latest News